- 著者
-
田中 司朗
大庭 幸治
吉村 健一
手良向 聡
- 出版者
- 日本計量生物学会
- 雑誌
- 計量生物学 (ISSN:09184430)
- 巻号頁・発行日
- vol.31, no.1, pp.23-48, 2010-07-31 (Released:2010-12-14)
- 参考文献数
- 71
- 被引用文献数
-
1
1
Surrogate endpoints, which represent a compromise in the conflict between measurability and clinical relevance of endpoints, have considerable advantage in rapid drug approvals compared to true endpoints in confirmatory clinical trials dealing with life-threatening diseases, such as cancer or AIDS. However, past experiences have shown the risk of relying too heavily on surrogate endpoints. In this paper, we review statistical criteria for evaluating surrogate endpoints and the past examples properly evaluated the surrogacy, taking into consideration relevant clinical and statistical issues.